Mylan Launches Generic Concerta® Tablets

HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen’s Concerta® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

http://newsroom.mylan.com/2016-12-29-Mylan-Launches-Generic-Concerta-Tablets

コメントを残す

メールアドレスが公開されることはありません。 * が付いている欄は必須項目です